About 85%–90% of patients in this group have X-linked agammaglobulinemia (XLA) due to mutations in the Bruton tyrosine kinase gene (BTK) (87), and 5% of patients have immunoglobulin μ heavy chain deficiency. This evidence concerns the gene BTK and X-linked agammaglobulinemia.